Letter

Stockpiling oseltamivir: Roche clarifies data for improved mortality with oseltamivir

BMJ 2005; 331 doi: 10.1136/bmj.331.7526.1203-b (Published 17 November 2005)
Cite this as: BMJ 2005;331:1203.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. James R Smith (james.smith.js1@roche.com), international medical leader,
  2. Regina Dutkowski, clinical science leader
  1. F Hoffman-La Roche, CH-4070 Basel, Switzerland
  2. Hoffmann-La Roche, Nutley, NJ 07110, USA

    EDITOR—Experts question the wisdom of stockpiling oseltamivir (Tamiflu).1 A question was asked about data supporting an improvement in mortality with the drug.

    Two datasets were presented at the second European Influenza Conference in Malta (http://www.eswi.org/) in September. A large retrospective cohort study of patients with influenza-like illness (n= 176 001) taken from a US health database showed …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular